Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Felcisetrag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 20/20 | 0.76 |
| ▸ | HTR3A | P46098 | 10/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felcisetrag SCHEMBL390795 | 0.86 | HTR4 (1.00) | HTR4HTR3A | |
| Felcisetrag SCHEMBL4361880 | 0.86 | HTR4 (0.98) | HTR4HTR3A | |
| SCHEMBL827475 | 0.79 | HTR4 (0.86) | HTR4HTR3A | |
| SCHEMBL828330 | 0.79 | HTR4 (0.85) | HTR4HTR3A | |
| SCHEMBL828734 | 0.78 | HTR4 (0.84) | HTR4HTR3A | |
| SCHEMBL1724211 | 0.78 | HTR4 (0.87) | HTR4HTR3A | |
| SCHEMBL829424 | 0.76 | HTR4 (0.76) | HTR4HTR3A | |
| SCHEMBL828614 | 0.76 | HTR4 (0.76) | HTR4HTR3A | |
| SCHEMBL1726589 | 0.76 | HTR4 (0.80) | HTR4HTR3A | |
| SCHEMBL828983 | 0.75 | HTR4 (0.82) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8404711-B2 | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | THERAVANCE, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2419104-A2 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | Theravance, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120695-A2 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100261752-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261752-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | HTR4, HTR5A, HTR3B | HTR4 1/4885HTR3A 6/4885CYP3A4 244/4885 |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | HTR4, HTR5A, HTR3B | HTR4 1/4885HTR3A 6/4885CYP3A4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.